Sirnaomics | GenomeWeb

Sirnaomics

The company is also pushing ahead with a microRNA-replacement therapy that is designed to improve patient response to colon cancer treatment.

Sirnaomics this week released preclinical data showing that two siRNAs against different strains of human papillomavirus could halt growth of papillomas in an animal model of HPV infection.

Sirnaomics could begin phase I testing of its siRNA-based wound-healing drug candidate STP-705 as soon as next year and expects to run the trial in China, a company official told Gene Silencing News this week.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

The combined grants are worth nearly $650,000 and are meant to support work on treatments for cancer and Huntington's disease.

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

The two areas, which have opportunities RXi's CEO called "tremendous" and "significant," have been well worn by rival drug companies making similar bets including Sirnaomics, TransDerm, and Quark Pharmaceuticals.

The company said the deal gives it access to the technology in the areas of wound healing and ocular diseases.

The six-month grant began on June 1 and is worth $250,000. The company will use the funds to develop multi-targeted siRNA drugs for non-small cell lung cancer.

Pages

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.